公司资料
Cingulate Inc. 股价、新闻与催化剂
- 股票代码:
- CING
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.21 USD (+2.36%)
收盘价
最后更新: 2026年8月17日
54.3M USD
市值
股价为何变动
As of Aug 17, 2026, CING closed up 2.36% at $5.21. No new same-company headline was identified in the current news window.
公司概览
Precision Timed Release Platform
Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence.
CTx-1301 ADHD Candidate
CTx-1301 is a once-daily, multi-core dexmethylphenidate hydrochloride tablet for attention-deficit/hyperactivity disorder. It is designed to provide rapid onset and efficacy throughout the active day and is being reviewed through the FDA’s 505(b)(2) pathway.
505(b)(2) Development Model
The regulatory strategy uses an established active pharmaceutical ingredient while seeking approval for a differentiated release profile and dosage form. This allows Cingulate to focus development on pharmacokinetics, duration of effect, manufacturing, and product-specific clinical performance.
Commercial Readiness
Cingulate is preparing payer access, distribution, supply chain, artificial intelligence-supported marketing technology, commercial manufacturing, and a sales organization for CTx-1301. Launch remains dependent on FDA approval.
未来催化剂
- Resubmission of the CTx-1301 NDA after completion of the requested manufacturing and CMC work.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。